The Cytox genoSCORE powered tests assess the genetic risk for Alzheimer’s disease. In the US: http://alzheimers-risk-test.com In Europe: http://genoscore-lab.com
Location: United Kingdom, England, Oxford
Total raised: $5.81M
Founded date: 2013
Investors 6
| Date | Name | Website |
| - | Qi3 Ventur... | qi3.co.uk |
| - | Esperante | esperante.... |
| - | Oxford Uni... | innovation... |
| - | Oxford Inv... | oxfordinve... |
| - | Walking Ve... | walking.vc |
| - | Greenwood ... | gwcinvesto... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.06.2017 | - | $3.32M | - |
| 03.04.2014 | - | $2.49M | - |
Mentions in press and media 15
| Date | Title | Description |
| 12.03.2019 | Cardiff University and Cytox to present further results on the implementation of SNPfitR analytical platform in identifying individuals for Alzheimer’s clinical trials at AD/PD conference in Lisbon | Study to show high accuracy of SNPfitR in predicting Alzheimer’s risk in both carriers and non-carriers of ApoE4 OXFORD & MANCHESTER, England–(BUSINESS WIRE)–March 13, 2019– Cytox, a precision medicine company which today is commerciali... |
| 23.09.2018 | Cytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress to Alzheimer’s | Important research collaboration for pioneering PRS approach to help drug developers running clinical trials identify and stratify between slow and rapid progressors of the disease OXFORD, England & MANCHESTER, England–(BUSINESS WIRE)–S... |
| 21.05.2018 | Cytox Launches Collaboration Agreement with Mayo Clinic to Evaluate Novel Genetic Based Approaches for Assessing Alzheimer’s Risk | Important research collaboration for pioneering PRS approach OXFORD, England & MANCHESTER, England–(BUSINESS WIRE)–May 22, 2018– Cytox, a precision medicine front-runner which today is commercializing polygenic risk scoring (PRS) approa... |
| 07.05.2018 | Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Risk to Include Saliva Samples | Pioneering PRS approach verified for banked DNA, blood and saliva samples OXFORD, England & MANCHESTER, England & ATLANTA–(BUSINESS WIRE)–May 8, 2018– Cytox, a precision medicine testing company commercializing polygenic risk scorin... |
| 07.03.2018 | Cytox Awarded New Innovate UK Funding for Alzheimer’s Testing | Important clinical evaluation of pioneering approach for risk assessment OXFORD, England & MANCHESTER, England–(BUSINESS WIRE)–March 8, 2018– Cytox, an emerging precision medicine leader providing genetic testing for Alzheimer’s disease... |
| 21.07.2016 | Cytox launches breakthrough genetic biomarker research assay for Alzheimer’s disease risk assessment | Simple blood-based test will help reduce screening failure in clinical trials and assist drug discovery OXFORD, England–(BUSINESS WIRE)–July 22, 2016– Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dement... |
| 12.10.2015 | Cytox Announces Participation in INSIGHT Alzheimer’s Study | Participation will aid comparison of SNP genotyping with biomarker status OXFORD, England–(BUSINESS WIRE)–October 12, 2015– Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has confirmed its parti... |
| 20.07.2015 | Cytox and Affymetrix Form Strategic Partnership to Develop and Commercialize Blood-Based Genetic Assay for Alzheimer’s Disease Risk Assessment | OXFORD, England–(BUSINESS WIRE)–July 20, 2015– Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, and Affymetrix (Nasdaq:AFFX), a leading provider of translational research and diagnostic solutions,... |
| 01.06.2015 | Cytox Signs Research Agreement with AIBL and Partner Organisations | Collaboration will contribute to further refinement of diagnostic SNPs for Alzheimer’s disease OXFORD, England–(BUSINESS WIRE)–June 1, 2015– Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has en... |
| 20.04.2015 | Cytox Awarded Innovate UK Funding for Stratification of Neurodegenerative Diseases | Funding will aid clinical evaluation of genetic panel in MCI risk stratification OXFORD, UK–(BUSINESS WIRE)–April 20, 2015– Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, is pleased to announce ... |
Show more